Browse All
Displaying 1 - 1 of 1
Author:Cohen, Jeffrey Hauser, Stephen Zielman, Ronald Das Gupta, Ayan Azmon, Amin Xi, Jing Mavrikis Cox, Gina Robertson, Derrick Wiendl, Heinz Kappos, Ludwig
Session Name:S16: MS Clinical Trials and Therapeutics
Topic:MS and Inflammatory Disease
Program Number:S16.009
Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA, San Francisco, CA Central Texas Neurology Consultants, Round Rock, TX, USA, Round Rock, TX Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India Novartis Pharma A.G., Basel, Switzerland, Basel, Switzerland China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, China, Shanghai, China, People's Republic of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL University of Muenster, Muenster, Germany, Muenster, Germany Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland
